Cancer Research UK have awarded a grant of £1.4 million to carry out the CaPP3 Study - a double blind randomised controlled dose inferiority trial of aspirin prevention in people with Lynch syndrome: high risk of cancer due to mutations in the mismatch repair genes.

Due to this funding, the CaPP3 website is currently going through regulatory processes.  Full details of the trial will be made available at the end of 2013.

If you have any queries please contact us.